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ABSTRACT
Members of the genus Campylobacter are notorious for their ability to cause gastroenteritis. However,
increasing numbers of case reports now suggest that they may have a wider pathogenic repertoire.
Pericarditis and myocarditis are increasingly being recognised as sequelae of Campylobacter infection.
Although rare, these presentations are important, as misdiagnosis may result in inappropriate
thrombolysis or angioplasty, with potential accompanying complications. Extraintestinal Campylobacter
infections, and the resulting pathogenesis, remain an important challenge for the 21st century,
particularly as immunocompromised patients are likely to become increasingly common.
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The genus Campylobacter gained much of its
notoriety from the ability of members of the
genus to cause gastroenteritis. Campylobacter jejuni
enteritis is the commonest enteric infection in the
developed world, with an annual incidence as
high as 1 in 1000. However, increasing numbers of
case reports now suggest that Campylobacter spp.
have a wider pathogenic repertoire than origin-
ally thought. Thus, Campylobacter fetus, type spe-
cies, has been identiﬁed as the causative agent of
pericarditis in at least ten documented cases
[1–10]. In these cases, patients present typically
with a history of several weeks of non-speciﬁc
symptoms, including fever, weight loss, cough
and chest pain. Signiﬁcantly, there is no reported
association with gastrointestinal symptoms in
these cases. C. jejuni pericarditis is also an
extremely rare entity, with only one reported case
[11], in which the patient suffered from a con-
genital immunodeﬁciency, X-linked agamma-
globulinaemia. The disease process ran an
aggressive course, and the patient was hospital-
ised for 6 weeks. Pericarditis was an element in a
presentation of systemic campylobacteriosis in
which both lungs and pericardium were signiﬁ-
cantly invaded. C. jejuni was isolated from blood
cultures, pleural effusion aspirate and pericardial
effusion aspirate.
There have also been six reported instances of
C. jejuni-associated myocarditis [12–17] and six
cases of C. jejuni-associated myopericarditis
[7–22], all of which involved immunocompetent
hosts. The typical clinical presentation involved
transient acute chest pain, with concomitant
electrocardiogram changes and elevated levels
of cardiac enzymes, in association with antece-
dent or coincident enteritis. In one case of
C. jejuni myocarditis, left ventricular function
was severely compromised for several months
following infection [14]. In another, the patient
suffered acute left ventricular failure on the
second day of admission, which subsequently
resolved within 24 h [16].
The precise mechanism by which Campylobacter
mediates myopericarditis remains unknown,
although there are several interesting putative
mechanisms. The ﬁrst involves direct attack of the
pericardium or myocardium by the bacterium or
its toxin following an episode of bacteraemia.
However, while C. fetus is almost invariably
isolated from blood in instances where the patho-
gen is linked to myopericarditis, the same cannot
be said for C. jejuni. Thus, the infective agent was
isolated from blood in nine of the ten cases of
C. fetus pericarditis (in the remaining case it
was isolated from the pericardial ﬂuid [3]), while
there was not a single instance among the
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12 cases of C. jejuni-associated myocarditis and
myopericarditis in which the organism was isola-
ted from blood. In these latter cases, the causative
agent was identiﬁed on the basis of positive stool
cultures and ⁄ or serological analyses.
Subtle differences in the presentation of C. fetus
and C. jejuni myopericardial infections may be
explained by nuances in their pathogenicity.
Extraintestinal manifestations of C. fetus are
legion, and result typically from direct pathogenic
invasion. Conditions described include septic
abortion, meningoencephalitis, brain abscesses,
subdural empyema, septic arthritis, vertebral
osteoarthritis, osteomyelitis and lung abscesses
[5,6]. The spectrum of extraintestinal sites of
infection has been linked to the pathogen’s ability
to elude the host immune system by means of
surface-layer proteins. These proteins render the
pathogen simultaneously impervious to comple-
ment attack and act as a means of antigenic
variation. This ‘S-layer protein’ impedes the
binding of complement C3b to the microbial
surface, thereby rendering it resistant to antibody
and phagocytic attack [23].
It is feasible that this protein coat, which
affords C. fetus protection against the host’s
immune system, enables the pathogen to use
the bloodstream as a system of transport from
the gut to secondary sites of infection, partic-
ularly in a host whose immune system is
weakened partially by chronic disease. Six of
the case reports involved patients with concom-
itant chronic disease, namely rheumatic fever [1],
lymphoma [2], hypothyroidism [3], polycystic
kidneys [4], b-thalassaemia [5] and diabetes
mellitus with hypertension [6]. C. fetus pericar-
ditis appears to be the result of colonisation of
the pericardium following bacteraemia and
septicaemia; hence the presentation with non-
speciﬁc symptoms such as fever, malaise and
weight loss. C. jejuni lacks the S-layer protein
coat, and appears to cause pernicious bacterae-
mia only in a profoundly immunocompromised
host [11]. It may well be that direct microbial
invasion of the pericardium via the blood is the
patho-aetiogenesis of C. fetus pericarditis, but not
of C. jejuni myopericarditis.
The second pathogenic paradigm involves a
type II hypersensitivity reaction, in which anti-
gens within Campylobacter and ⁄ or its toxin cross-
react with pericardial antigens; alternatively,
Campylobacter and ⁄ or its toxin may display anti-
gens similar to those of the pericardium. This
molecular mimicry may temper the host’s
immune response against the invader. Antibodies
generated against the invading pathogen thus
attack both pericardium and pathogen. There is
typically a temporal window of several weeks
between the primary infection and the develop-
ment of hypersensitivity reactions.
In all except two of the cases in which C. jejuni
has been implicated in myopericarditis and
myocarditis, the gastrointestinal and cardiac
symptomologies were coincident, making an
immunological aetiology unlikely. In the two
exceptions, both patients presented with cardiac
involvement 2 weeks after the onset of enteric
symptoms [18]. In addition, both patients suffered
from concomitant reactive arthritis. Interestingly,
C. jejuni has been linked to a number of patholo-
gies by means of immunological mechanisms.
Thus, reactive arthritis is a recognised complica-
tion in 1% of symptomatic C. jejuni enteric infec-
tions. Similarly C. jejuni enteritis is an antecedent
event in 26–41% of patients suffering from Guil-
lan–Barre´ syndrome. There is typically a period of
several weeks between the onset of enteric symp-
toms and the development of these pathologies.
With the advent of antibiotics, it was thought
that mankind would be ﬁnally victorious in the
war against microbial infection. However, three
interlinked phenomena have tilted the balance of
power surreptitiously towards the pathogen. The
ﬁrst is antibiotic resistance, with the increasingly
liberal use of antibiotics within human and
animal populations [24]. The second is the
increasingly common pathogenically or iatrogen-
ically immunocomprised patient. The third is the
phenomenon of increasingly epidemic enteric
pathogens, such as Campylobacter spp. Such
organisms use their pandemic status in the form
of enteritis as springboards to attack other organ
systems by novel pathogenic mechanisms, which
currently remain unidentiﬁed. In particular, peri-
carditis and myocarditis are recognised increas-
ingly as sequelae of Campylobacter infection.
Although rare, they are noteworthy manifesta-
tions of infection with this pathogen, as misdiag-
nosis may result in inappropriate thrombolysis or
angioplasty. Extraintestinal Campylobacter infec-
tions and pathogenicity remain a challenge for the
21st century, particularly as immunocompro-
mised patients are likely to become increasingly
common.
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